Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rodatristat ethyl (KAR5585) is a first-of-its-kind orally active and potent tryptophan hydroxylase 1 (TPH1) inhibitor that significantly reduces 5-hydroxytryptamine (5-HT) levels and decreases pulmonary arterial hypertension (PAH) at low concentrations.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,390.00 | |
50 mg | 10-14 weeks | $ 3,870.00 | |
100 mg | 10-14 weeks | $ 6,230.00 |
Description | Rodatristat ethyl (KAR5585) is a first-of-its-kind orally active and potent tryptophan hydroxylase 1 (TPH1) inhibitor that significantly reduces 5-hydroxytryptamine (5-HT) levels and decreases pulmonary arterial hypertension (PAH) at low concentrations. |
In vivo | In male Sprague-Dawley rats, oral administration of rodatristat ethyl at doses of 100 or 200 mg/kg once daily for 28 days results in a dose-dependent decrease in serum, gut, and lung 5-HT levels. This treatment significantly reduces pulmonary arterial pressure as well as pulmonary vessel wall thickness and occlusion in rats with monocrotaline (MCT)-induced pulmonary hypertension[2]. |
Synonyms | RVT-014, KAR5585, RVT-1201 |
Molecular Weight | 590.04 |
Formula | C29H31ClF3N5O3 |
CAS No. | 1673571-51-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (152.53 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rodatristat ethyl 1673571-51-1 GPCR/G Protein Metabolism Neuroscience Hydroxylase 5-HT Receptor RVT-014 KAR-5585 KAR 5585 KAR5585 RVT-1201 inhibitor inhibit